INOVIO (NASDAQ: INO) CFO awarded 31,240 options and 25,520 RSUs

Rhea-AI Filing Summary

INOVIO PHARMACEUTICALS, INC. CFO Peter Kies received equity awards in the form of stock options and restricted stock units on March 4, 2026. He was granted 31,240 common stock options at an exercise price of $0.0000 per share, all held as direct ownership.

The options vest in three installments: 10,414 shares on February 26, 2027, 10,413 shares on February 26, 2028, and 10,413 shares on February 26, 2029. He was also granted 25,520 restricted stock units, each representing a contingent right to receive one share of common stock, with 8,507 units vesting on February 26, 2027, 8,507 on February 26, 2028, and 8,506 on February 26, 2029. Vested restricted stock units can be settled in common stock, cash, or a combination of both.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider KIES PETER

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Option	31,240	$0.00	--
Grant/Award	Restricted Stock Unit	25,520	$0.00	--

Holdings After Transaction: Common Stock Option — 31,240 shares (Direct); Restricted Stock Unit — 25,520 shares (Direct)

Footnotes (1)

1. The vesting schedule for the 31,240 options granted on March 4, 2026 was as follows: 10,414 shares will vest on February 26, 2027; 10,413 shares will vest on February 26, 2028; 10,413 shares will vest on February 26, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,520 restricted stock units granted on March 4, 2026 was as follows: 8,507 shares will vest on February 26, 2027; 8,507 shares will vest on February 26, 2028; and 8,506 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIES PETER

(Last) (First) (Middle)

C/O INOVIO PHARMACEUTICALS, INC.

6769 MESA RIDGE ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	$1.73	03/04/2026		A		31,240		(1)	02/26/2036	Common Stock	31,240	$0	31,240	D
Restricted Stock Unit	(2)	03/04/2026		A		25,520		(2)	(2)	Common Stock	25,520	$0	25,520	D

Explanation of Responses:

1. The vesting schedule for the 31,240 options granted on March 4, 2026 was as follows: 10,414 shares will vest on February 26, 2027; 10,413 shares will vest on February 26, 2028; 10,413 shares will vest on February 26, 2029.

2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,520 restricted stock units granted on March 4, 2026 was as follows: 8,507 shares will vest on February 26, 2027; 8,507 shares will vest on February 26, 2028; and 8,506 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Remarks:

	/s/ Peter Kies	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did INO CFO Peter Kies receive on March 4, 2026?

On March 4, 2026, CFO Peter Kies received 31,240 common stock options and 25,520 restricted stock units as direct holdings. These derivative awards provide potential future ownership in INOVIO PHARMACEUTICALS, INC., subject to multi-year vesting schedules and applicable settlement terms.

How do the 31,240 INO stock options granted to the CFO vest?

The 31,240 stock options vest in three tranches over three years. 10,414 options vest on February 26, 2027, 10,413 vest on February 26, 2028, and 10,413 vest on February 26, 2029, creating a staggered vesting schedule for the award.

What is the vesting schedule for the 25,520 INO restricted stock units?

The 25,520 restricted stock units vest in three installments. 8,507 units vest on February 26, 2027, another 8,507 units vest on February 26, 2028, and 8,506 units vest on February 26, 2029, aligning the award with a three-year vesting period.

What does each INO restricted stock unit granted to the CFO represent?

Each restricted stock unit represents a contingent right to receive one share of INOVIO common stock. Once vested, these units may be settled in shares, cash, or a combination of both, providing flexibility in how the award is ultimately delivered.

Are the INO equity awards to CFO Peter Kies classified as direct ownership?

Yes, the Form 4 classifies both the 31,240 stock options and the 25,520 restricted stock units as directly owned. The ownership code and direct_or_indirect indicators both show “D,” indicating direct rather than indirect beneficial ownership of these awards.

Was there a purchase price for the 31,240 INO stock options granted?

The reported transaction price per share for the 31,240 common stock options is $0.0000. This reflects the grant terms disclosed for the derivative award on March 4, 2026, rather than an open-market purchase of existing common shares.